The complexities of managing the care of a rare disease patient are tremendous. Several models of care are efficient when optimizing patient care...
Recurrent Pericarditis (RP) is a painful auto-inflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or...
Often when pharmacy benefit manager (PBM) agreements and specialty pharmacy agreements are put into place, no one considers the 1 or 2 percent of the...
Whether it's open, limited, or exclusive, the main goal of all healthcare distribution network systems should be to provide patients access to the...
Traditional specialty drugs for diseases such as rheumatoid arthritis and multiple sclerosis are best served under an open distribution model where...
Before any anticipated specialty drug launch, a pharmaceutical manufacturer conducts an extensive market access evaluation to determine the best...
According to the National Institutes of Health (NIH), approximately 7,000 rare diseases affect between 25 and 30 million Americans (almost 1 in 10)1....
Almost 1 in 10 Americans are affected by a rare disease.1 Common challenges rare disease patients face include limited treatment options, little to no...
Tardive Dyskinesia (TD) is a neurological movement disorder typically characterized by repetitive, involuntary movements of the jaw, lips, and tongue....
Mucopolysaccharidosis (MPS) is an inherited metabolic disease in which the body does not produce enough enzymes to break down sugars into simpler...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
Optimizing Patient Care Services with Rare Disease Limited Distribution Drugs
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)